{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:53Z","timestamp":1791912473455,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12325-026-03543-1","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:38:03Z","timestamp":1773329883000},"page":"2125-2138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis"],"prefix":"10.1007","volume":"43","author":[{"given":"Saiju","family":"Jacob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Hashim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzy","family":"Van Sanden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Slowik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Drudge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine C. El","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Jun","family":"Keng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu","family":"Ramchandren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils Erik","family":"Gilhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"3543_CR1","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.12688\/f1000research.8206.1","volume":"5","author":"W Phillips","year":"2016","unstructured":"Phillips W, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Research. 2016;5:1513.","journal-title":"F1000Research"},{"issue":"1","key":"3543_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"3543_CR3","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s12325-023-02604-z","volume":"40","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Phillips G, Paci S, et al. People diagnosed with myasthenia gravis have lower health-related quality of life and need more medical and caregiver help in comparison to the general population: analysis of two observational studies. Adv Ther. 2023;40(10):4377\u201394.","journal-title":"Adv Ther"},{"issue":"7","key":"3543_CR4","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1080\/03007995.2024.2353381","volume":"40","author":"M Zhdanava","year":"2024","unstructured":"Zhdanava M, Pesa J, Boonmak P, et al. Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG-events. Curr Med Res Opin. 2024;40(7):1145\u201353.","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"3543_CR5","first-page":"2","volume":"13","author":"C Casasnovas","year":"2025","unstructured":"Casasnovas C, Claeys KG, Vissing J. Long-term patient outcomes: the role of sustained treatment efficacy in myasthenia gravis. Eur Med J. 2025;13(Suppl 1):2\u20137.","journal-title":"Eur Med J"},{"issue":"2","key":"3543_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","volume":"39","author":"L Gerischer","year":"2025","unstructured":"Gerischer L, Doksani P, Hoffmann S, Meisel A. New and emerging biological therapies for myasthenia gravis: a focussed review for clinical decision-making. BioDrugs. 2025;39(2):185\u2013213.","journal-title":"BioDrugs"},{"issue":"3","key":"3543_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"4","key":"3543_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"D Sanders","year":"2016","unstructured":"Sanders D, Wolfe GI, Benatar M, Evoli A, Gilhus NE. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87(4):419.","journal-title":"Neurology"},{"issue":"2","key":"3543_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","volume":"24","author":"C Antozzi","year":"2025","unstructured":"Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase\u00a03, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105\u201316.","journal-title":"Lancet Neurol"},{"key":"3543_CR10","unstructured":"United States Food and Drug Administration. Imaavy (nipocalimab-aahu) injection, for intravenous use (Highlights of prescribing information). 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761430s000lbl.pdf. Accessed August 23, 2025."},{"key":"3543_CR11","unstructured":"European Medicines Agency. Imaavy: EPAR - product information (Summary of product characteristics). 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imaavy-epar-product-information_en.pdf. Accessed December 12, 2025."},{"key":"3543_CR12","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase\u00a03 trial. Lancet Neurol. 2021;20:526\u201336.","journal-title":"Lancet Neurol"},{"key":"3543_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Druzdz A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised double-blind, placebo-controlled, adaptive phase\u00a03 study. Lancet Neurol. 2023;22:383\u201394.","journal-title":"Lancet Neurol"},{"key":"3543_CR14","unstructured":"European Medicines Agency. Vyvgart: EPAR - product information (Summary of product characteristics). 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vyvgart-epar-product-information_en.pdf. Accessed August 23, 2025."},{"key":"3543_CR15","unstructured":"European Medicines Agency. Rystiggo: EPAR - product information (Summary of product characteristics). 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rystiggo-epar-product-information_en.pdf. Accessed August 23, 2025."},{"key":"3543_CR16","unstructured":"United States Food and Drug Administration. Vyvgart (efgartigimod alfa-fcab) injection, for intravenous use (Highlights of prescribing information). 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761195s000lbl.pdf. Accessed August 23, 2025."},{"key":"3543_CR17","unstructured":"United States Food and Drug Administration. Rystiggo (rozanolixizumab-noli) injection, for subcutaneous use (Highlights of prescribing information). 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761286s001lbl.pdf. Accessed August 23, 2025."},{"issue":"3","key":"3543_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-091961","volume":"15","author":"JD Guo","year":"2025","unstructured":"Guo JD, Gehchan A, Hartzema A. Selection of indirect treatment comparisons for health technology assessments: a practical guide for health economics and outcomes research scientists and clinicians. BMJ Open. 2025;15(3):e091961.","journal-title":"BMJ Open"},{"issue":"1","key":"3543_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12325-024-03013-6","volume":"42","author":"A Igarashi","year":"2025","unstructured":"Igarashi A, Tanaka S, De Moor R, et al. Indirect treatment comparisons in healthcare decision making: a targeted review of regulatory approval, reimbursement, and pricing recommendations globally for oncology drugs in 2021\u20132023. Adv Ther. 2025;42(1):52\u201369.","journal-title":"Adv Ther"},{"issue":"6","key":"3543_CR20","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2025-0009","volume":"14","author":"NE Gilhus","year":"2025","unstructured":"Gilhus NE, Jacob S, Hashim M, et al. Network connectivity, between-study heterogeneity and timepoint challenges in generalized myasthenia gravis: a feasibility assessment of indirect treatment comparisons. J Comp Eff Res. 2025;14(6):e250009.","journal-title":"J Comp Eff Res"},{"issue":"6","key":"3543_CR21","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137.","journal-title":"Value Health"},{"key":"3543_CR22","unstructured":"Phillippo DM, Ades AE, Dias S, et al. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submission to NICE. 2016.  https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/full-list. Accessed August 23, 2025."},{"issue":"6","key":"3543_CR23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683\u201391.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"3543_CR24","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0021","volume":"12","author":"G Fawsitt Christopher","year":"2023","unstructured":"Fawsitt Christopher G, Thom H, Regnier Stephane A, et al. Comparison of indirect treatment methods in migraine prevention to address differences in mode of administration. J Comp Eff Res. 2023;12(7):e230021.","journal-title":"J Comp Eff Res"},{"key":"3543_CR25","unstructured":"Federal Joint Committee (G-BA). Assessment for Efgartigimod alfa. 2022. https:\/\/www.g-ba.de\/downloads\/92-975-6020\/2022_08_31_Modul4A_Efgartigimod_alfa.pdf. Accessed August 16, 2025."},{"key":"3543_CR26","unstructured":"argenx. ADAPT Clinical Trial Protocol. 2019. https:\/\/cdn.clinicaltrials.gov\/large-docs\/88\/NCT03669588\/Prot_000.pdf. Accessed August 16, 2025."},{"key":"3543_CR27","unstructured":"European Medicines Agency. Orphan designation withdrawal assessment report for Zilbrysq (zilucoplan). 2023. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-maintenance-report\/zilbrysq-orphan-designation-withdrawal-assessment-report_en.pdf. Accessed August 16, 2025."},{"issue":"6","key":"3543_CR28","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1007\/s12325-024-02856-3","volume":"41","author":"C van Steen","year":"2024","unstructured":"van Steen C, Celico L, Spaepen E, et al. Efgartigimod and ravulizumab for treating acetylcholine receptor auto-antibody-positive (AChR-Ab+) generalized myasthenia gravis: indirect treatment comparison. Adv Ther. 2024;41(6):2486\u201399.","journal-title":"Adv Ther"},{"key":"3543_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1280226","volume":"14","author":"H Chen","year":"2023","unstructured":"Chen H, Qiu Y, Yin Z, Wang Z, Tang Y, et al. Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis. Front Immunol. 2023;14:1280226.","journal-title":"Front Immunol"},{"key":"3543_CR30","unstructured":"Smith AG, Wolfe GI, Habib AA, et al. Network meta-analysis of treatment options in generalized myasthenia gravis: evaluating the comparative effectiveness of emerging immunomodulatory therapies. In: Poster presented at the American Academy of Neurology (AAN) Annual Meeting 2025; San Diego, California."},{"issue":"2","key":"3543_CR31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40263-024-01062-7","volume":"38","author":"Y Ma","year":"2024","unstructured":"Ma Y, Nie X, Zhu G, et al. The efficacy and safety of different targeted drugs for the treatment of generalized myasthenia gravis: a systematic review and Bayesian network meta-analysis. CNS Drugs. 2024;38(2):93\u2013104.","journal-title":"CNS Drugs"},{"issue":"12","key":"3543_CR32","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","volume":"30","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Pane C, Espinosa PE, Sormani MP, Signori A. Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. Eur J Neurol. 2023;30(12):3854\u201367.","journal-title":"Eur J Neurol"},{"issue":"12","key":"3543_CR33","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.jval.2022.09.201","volume":"25","author":"L Celico","year":"2022","unstructured":"Celico L, Spaepen E, De Francesco M, Iannazzo S. An indirect comparison of efgartigimod versus rituximab for generalized myasthenia gravis (CO123). Value Health. 2022;25(12):S42.","journal-title":"Value Health"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03543-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03543-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03543-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:38:01Z","timestamp":1778229481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03543-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3543"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03543-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Johnson & Johnson, who had a role in study design, analysis, interpretation, and manuscript development. Saiju Jacob has served as an international advisory board member or has been in the data monitoring committee for clinical trials for Johnson & Johnson, Alexion, Alnylam, Argenx, Immunovant, Merck, Novartis, Regeneron and UCB pharmaceuticals, is currently an expert panel member of Myasthenia Gravis consortium for Argenx pharmaceuticals and has received speaker fees from Argenx, Eisai, Terumo BCT and UCB pharmaceuticals. He is also a board member (trustee) of the UK myasthenia patient charity, Myaware. Mahmoud Hashim, Kavita Gandhi, Suzy Van Sanden, Rafal Slowik, Antoine C. El Khoury, Mi Jun Keng, and Sindhu Ramchandren are employees of Johnson & Johnson and may hold stock\/stock options of Johnson & Johnson. Brian Hutton has previously received honoraria from Johnson & Johnson, EVERSANA, Maple Health Group, Stratenym, and Evidinno Outcomes Research Inc. for provision of methodologic advice related to the conduct of systematic reviews, meta-analyses, and indirect treatment comparisons. Christopher Drudge and Sumeet Singh are employees of EVERSANA. EVERSANA receives consultancy fees from pharmaceutical and device companies, including Johnson & Johnson. Nils Erik Gilhus has received consultative or speaker\u2019s honoraria from Johnson & Johnson, UCB, Argenx, Alexion, Merck, Dianthus, Amgen, Roche, Grifols, Immunovant, Huma, Denka, Novartis, NMD Pharma, Lundbeck, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study used only data from previously conducted clinical trials, so institutional review board approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}